Yakdan Al Qaisi, MD
Family Medicine · Bakersfield, CANPI 1811068869
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $199 and has fallen 58.5% since, to $83 in 2025.
Across 42 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$99
- Pfizer$84
- Novo Nordisk$74
- Lilly USA, LLC$73
- Amarin Pharma, Inc.$61
- AbbVie$49
- plus $332 from 13 others
Across 3 payments — averaging $106,515 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$232K
- AstraZeneca$87K
What the payments were for
- Food & beverage$772100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $99 |
| Pfizer | 4 | $84 |
| Novo Nordisk | 3 | $74 |
| Lilly USA, LLC | 4 | $73 |
| Amarin Pharma, Inc. | 3 | $61 |
| AbbVie(2 entities) | 3 | $49 |
| Merck | 3 | $47 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Abiomed | 1 | $36 |
| Radius Health, Inc. | 2 | $33 |
| Boston Scientific | 1 | $28 |
| Sunovion Pharmaceuticals Inc. | 4 | $27 |
| Baxter Healthcare | 1 | $23 |
| Amgen | 1 | $19 |
| GSK | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Gilead | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$772 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 39 | $41,941 |
| JardianceEmpagliflozin | 37 | $39,589 |
| OzempicSemaglutide | 25 | $23,573 |
| RybelsusSemaglutide | 15 | $19,393 |
| EliquisApixaban | 30 | $18,548 |
| JanuviaSitagliptin Phosphate | 16 | $18,479 |
| MounjaroTirzepatide | 16 | $16,416 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $12,073 |
| FarxigaDapagliflozin Propanediol | 11 | $11,517 |
| LinzessLinaclotide | 20 | $10,664 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $8,254 |
| VascepaIcosapent Ethyl | 17 | $7,879 |
| MovantikNaloxegol Oxalate | 14 | $5,339 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $4,219 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 160 | $2,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $73 | $58,35855 claims |
| Novo NordiskOzempic, Rybelsus | $74 | $42,96640 claims |
| MerckJanuvia, Janumet Xr | $47 | $26,73230 claims |
| PfizerEliquis | $84 | $18,54830 claims |
| AbbVieLinzess | $49 | $10,66420 claims |
| GSKArnuity Ellipta | $19 | $2,59711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.
Other family medicine in Bakersfield
- Amira AyadBakersfield$360K
- Matthew BeareBakersfield$98K
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.